Resistant Depression by Ontiveros, Jose Alfonso
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books









The term resistant points out a clinical phenomenon in which there is a lack of 
response to one or more therapeutic interventions. Resistance to major depressive 
disorder treatment causes distress to patients and their relatives, and increases 
the number of hospital admissions, outpatient consultations, use of psychoactive 
drugs, and treatment costs. Despite its serious medical and psychosocial medi-
cal implications, the definition of treatment resistant depression continues to be 
ambiguous and controversial. The lack of an agreement on definition, as well as the 
research on the subject being difficult, limits the practical knowledge on the best 
treatment options for groups of treatment resistant depression (TRD) patients. We 
review the concept and definitions of treatment resistant depression as well as the 
medical literature on different treatment methods studied and comparative studies. 
Finally, some relevant neurobiological data are reviewed.
Keywords: treatment, major depressive disorder, resistant depression, 
antidepressants, review
1. Introduction
The term “resistant” is widely employed in medical practice to point out a 
clinical phenomenon in which there is a lack of response to one or more therapeu-
tic interventions. The presence of treatment resistance implies a specific series 
of clinical interventions, typically multidisciplinary, and focuses on solving or 
minimizing a medical problem. Resistance to major depressive disorder treatment, 
but also to other depressive disorders, such as dysthymia and bipolar depression, 
causes distress to patients and their relatives, and increases the number of hospital 
admissions, outpatient consultations, the use of psychoactive drugs, and treat-
ment costs up to six times [1]. The definition of treatment resistant depression 
(TRD) continues to be ambiguous and controversial despite its serious medical and 
psychosocial implications. In medical literature, we can find more than 10 different 
definitions [2]. Many authors have published staging systems with their own defini-
tions, descriptions, and characteristics on TRD [3–7]. The most accepted definition 
is a lack of response to two different pharmacological classes of antidepressants 
[8]. However, this definition may seem simplistic today as published treatment 
results on TRD patients emerge. The lack of an agreed TRD definition as well as the 
difficulties to do research on the subject limit our practical knowledge on the best 
treatment options for groups of TRD patients.
We review the concept and definitions of TRD. We also review the medical 
literature on different treatment methods studied as well as comparative studies. 
Finally, we review some relevant emerging neurobiological data.
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2. Treatment resistance depression (TRD)
2.1 The concept of resistant depression
Although this phenomenon had already been described, many authors have intro-
duced the concept of TRD since 1974 [9, 10]. This concept arises at a time when there 
were only tricyclic, tetracyclic, and monoamine-oxidase inhibitors (MAOIs) antide-
pressants available. In spite of its importance, the definition of treatment resistance 
regarding major depression continues to be a wide and inconsistent notion. A review 
of the literature identifies a range of definitions for TRD that go from non-response 
to a single antidepressant (for 4 or more weeks) to lack of response to different classes 
of antidepressants and electroconvulsive therapy (ECT) [2]. Treatment should be 
appropriate in dose and duration [2, 11–13], and patients must have full compliance 
to it [13] to consider a patient as resistant to treatment. There is no consensus on the 
number of treatments and when these are indicators of resistance.
A dichotomic denomination has been proposed for resistant depression, viz. 
an absolute and a relative. Absolute resistance is an inappropriate anti-depressive 
response toward a treatment given for an appropriate period of time at the maxi-
mum non-toxic dose. On the other hand, relative resistance to treatment is defined 
when this is given at a suboptimal dose or duration [5, 10, 14]. The terms “chronic,” 
“refractory,” and “difficult-to-treat depression” have been employed as synonyms 
in the absence of a nonspecific number of clinical trials for one or more antidepres-
sants. Treatment refractory depression refers to major depression that does not 
respond to multiple sequential treatments. There is no clear difference between 
treatment resistant depression and refractory depression [5, 8, 11]. Chronicity, 
however, refers to a pathological clinical phenomenon that lasts for 2 or more years. 
There is no consensus on depressive symptom severity to consider it as resistant. It 
has been suggested that a score of 16 or more on the Hamilton depression 17-item 
scale (HAM-D) is enough to confirm the diagnosis. However, patients with persis-
tent mild or moderate depressive symptoms may have a worse prognosis than those 
in remission [15]. The definition of Berlim and Turecki [2], which considers TRD 
as an episode of major depression that has not improved after two proper attempts 
with different classes of antidepressants, prevails today. The European Medicine 
Agency (EMA), on a TRD definition review, considers it as a clinically relevant 
major depression that has not benefited from at least two appropriate attempts of 
treatment with at least two antidepressants with a different action mechanism [16]. 
The definition which considers TRD as an episode of major depression that has 
not improved after two proper attempts with different classes of antidepressants 
[2] seems to be backed up by the STAR*D study, which shows that improvement 
chances diminish after the second treatment failure [17, 18]. Treatment resistance 
to pharmacologic treatment seems to move on a continuum that ranges from total 
response to total resistance to therapeutic intervention and not as an all-or-nothing 
phenomenon [5, 19, 20]. However, no definition has been investigated regarding 
validity and predictability [5, 21]. Inconsistencies on the definition not only give 
rise to difficulties at estimating its prevalence [17, 22] but can also delay research of 
the most efficient treatment schemes.
2.2 Prevalence of resistant depression
In spite of pharmacological treatment advances in major depression, the final 
objective of achieving a sustained improvement continues to be insufficient [23]. 
It is estimated that about only 30–40% of patients achieve remission after the first 
attempt of treatment with antidepressants. In 3671 ambulatory patients treated 
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with escitalopram, only 37% achieved remission [18]. Even after an appropriate 
sequence of treatments, 10–20% of the patients with major depression continue 
with significant symptoms for 2 years or more [24, 25]. The STAR*D study 
(sequenced treatment alternatives to relieve depression study) showed that accu-
mulated remission after four treatment trials with antidepressants for 14 months 
was 67% [26]. Patients with chronic depression seem to have less opportunity for 
recovery [27] and tend to be more resistant to treatment [1, 28]. TRD is also associ-
ated to longer time of treatment and increased costs [29].
2.3  Antidepressant treatment resistance assessment scales and stratification 
systems
2.3.1 Antidepressant treatment assessment scales
From the multiple published assessment scales, three of them stand out in litera-
ture: the Antidepressant Treatment History Form [30], the Harvard Antidepressant 
Treatment History [31], and the Massachusetts General Hospital Antidepressant 
Treatment Response Questionnaire [6]. The clinician performs the former two; the 
latter is performed by the patient.
The Antidepressant Treatment History Form (ATHF; 1990; revised 1999) was 
originally designed to assess the efficacy of antidepressant treatment before ECT 
[30]. The scale has five treatment levels, which go from 0 (no treatment) to 5 (high 
antidepressant doses plus lithium or triiodothyronine (T3) for at least 4 weeks, 
including antipsychotics in patients with depression and psychotic symptoms. The 
scale has been modified and recently digitalized [32]. This scale has the disadvan-
tage of not including pharmacological combination strategies or preferences on 
switching treatment [33]. The Antidepressant Treatment History Form has been 
empirically validated with the monitoring of prospective treatment [8, 33–35]. The 
original ATHF version has a good inter-rater reliability [3], and the digitalized ver-
sion has an excellent inter-rater reliability as well, with another evaluator [32].
The Harvard Antidepressant Treatment History (HATH) allows to systemati-
cally assess the dose and duration of previous antidepressant medication trials. 
The patient identifies all the antidepressants taken from a list of all available once, 
a series of systematic questions over dose, duration, and response are asked to 
determine treatment response or resistance [31].
The Massachusetts General Hospital Antidepressant Treatment Response 
Questionnaire (ATRQ ) is an auto-evaluating scale that defines an appropriate 
antidepressant treatment as optimal dosage during 6 weeks. This questionnaire 
provides operational criteria for adequate dosing of each antidepressant and has 
been used on multiple multicentric studies in TRD. In one study, it was found that 
MGH and ATRQ agree with the independent evaluations of clinical researchers on 
remote interviews [36].
2.3.2 Treatment resistant depression stratification systems
Systems may help predict the ulterior course of depression on the long-term and 
its response to treatment [1]. It is important to point out that all systems based on 
treatment administration have limitations; they were designed when therapeutic 
options available at the time were more limited, and despite their clinical useful-
ness, they have not been properly validated.
Four stratification systems stand out in literature: the Staging Method of Thase 
and Rush [4], the European Staging Method [5, 37], the Massachusetts General 
Hospital Staging model (MGH-s) [6], and The Maudsley Staging Model (MSM) [7].
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Thase and Rush proposed five levels of resistance, in which patients are cat-
egorized according to the number and antidepressant class they have failed to 
respond, from the most frequently used to the least usual as MAOIs or ECT [4]. Not 
one degree of each therapeutic trial in terms of dose and duration is recorded; it 
assumes that the non-response to two antidepressant agents of different classes is 
more difficult to treat than the non-response to agents of the same group and that 
the change to an antidepressant of the same group is less effective. The later may 
be true for tricyclic antidepressants, but it is not so at switching between different 
serotonin reuptake inhibitors (SSRIs) [17]. This classification considers that the 
most effective antidepressants on order would be MAOIs, tricyclic antidepressants, 
and SSRIs, which has not been validated on different meta-analyses in antidepres-
sant trials [17, 20]. It also faces the disadvantage of not including other treatments, 
such as drug combinations and psychotherapy, and does not provide prognostic 
information [38]. The Thase and Rush scale is easy to implement and provides an 
accessible strategy for clinicians to treat TRD patients. However, it has been widely 
criticized recently, since its predictive value over the course of treatment has not 
been systematically evaluated [8, 33, 34].
A European Staging Method (ESM) proposes the classification between 
non-responders, patients with TRD, and chronic resistant depression (CRD). 
Non-responders are defined as patients who fail to respond to a method of treat-
ment. Patients are considered TRD if they show poor response to two treatment 
options with different classes of antidepressants at a proper dose over the span of 
6–8 weeks. CRD is defined as a resistant or refractory episode that lasts for more 
than a year despite appropriate therapeutic interventions. This scale has the advan-
tage of including the duration of the depressive episodes and does not suggest a 
hierarchy of antidepressants. Non-response is clearly defined as a reduction inferior 
to 50% on the score of the HAMD [39] or the Montgomery Asberg Depression 
Rating Scale (MADRS) [40] and the TRD stages correspond to the number of failed 
therapeutic trials. It is assumed that patients with failure to respond to two agents 
of different classes would be more resistant than those who do not respond to two 
drugs of the same group and indirectly implies that switching to a drug from the 
same class is less effective [6]. It should be noted that, in this classification, the dif-
ferences between TRD and CRD are arbitrary [8]. ESM does not establish that two 
or more attempts with failed antidepressants imply a higher level of TRD, in con-
trast with the publications that associate the number of changes with poor response 
to treatment [17, 18]. Furthermore, CRD does not consider non-pharmacological 
measures such as ECT or psychotherapy. To date, there are no studies that prove the 
predictive utility or reliability of the scale.
The Massachusetts General Hospital Staging model (MGH-s) was published 
for the first time by Fava [6] based on the scale by Thase and Rush. The MGH-s 
considers dosage optimization and separately prolonging the duration of treatment, 
as well as an operational criterion for minimal dose and duration of treatment. It 
includes measures for titration and combinations and does not rank antidepressant 
classes [41] or an implied preference between them or a change to the same group of 
drugs. The MGH-s considers the number of failed treatments and the intensity and 
optimization of each attempt and generates a continuous variable that reflects the 
degree of resistance to antidepressants. MGH-s generates a continuous score that 
reflects the level of resistance. However, this score is randomly given [8]. Dosage 
optimization and duration are considered equal to increase or combination, which 
does not seem to be backed up on literature [42–44]. Finally, the higher score given 
to ECT is not sufficiently explained [7, 45].
A study published a comparison between the MGH-s and the Thase and Rush 
Staging Method on a sample of 115 ambulatory patients with major depression. All 
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results showed that both models have a high correlation, but the multivariable analy-
sis demonstrated that the MGH-s had a better prediction for non-remission [45].
Fedaku et al. [7] published The Maudsley Staging Model (MSM) method of 
stratification, in which the TDR score varies from 3 to 15. TRD stages are shown 
in three categories: mild (scores 3–6), moderate (scores 7–10), and severe (scores 
11–15). It incorporates the duration and severity of the depressive episode. MSM 
considers class switching between different antidepressant groups, and between 
the same group has the same score. The scale is easy to use and may be employed 
as a tridimensional model regarding duration, severity, and treatment. It has been 
criticized, however, that disease duration is arbitrary and does not include the 
number of titrating attempts. Empiric value and inter-rate reliability was proven 
with prospective data obtained from the notes of 88 patients on a TRD specialized 
unit and follow-up of 62 patients in this group for a medium of 29.5 months [7].
2.4 Resistant depression treatment general principles
Qualitative and quantitative assessment of depressive symptoms with evaluation 
scales on each visit, assessment tool employment, and watching over adverse effects 
should be a routine practice in the approach to the patient with major depressive 
disorder, and even more so with the TRD patient. Furthermore, it is recommended 
to evaluate psychosocial performance, quality of life, treatment compliance and tol-
erance, and provide 24-h assistance [46]. It is important to encourage patients not 
to abandon treatment or medical attention despite of not perceiving any results. A 
good relationship between the clinician and the patient is also important to guaran-
tee treatment compliance [15]. Finally, the role of psycho-education for the patients 
and their relatives should not be forgotten, as this includes sign and symptom 
identification, prognosis, suicide risk assessment, treatment options, sleep hygiene, 
impulse control, and sleep restriction among others. Behind restriction the initial 
management of depressive patients is usually done by primary care physicians or 
internists, but they should be referred to a mental health specialist if there is not an 
appropriate response to two or more treatments, as well when suicidal or homicidal 
ideation, psychotic or catatonic behavior are detected.
2.4.1 Treatment strategies
For patients with major depressive disorder who do not respond to initial 
treatment with an antidepressant, there are diverse management strategies  
[5, 14, 30, 47–50] which have been classified and arranged in three groups as 
follows: (1) optimization; (2) treatment switching (to a different antidepressant, 
psychotherapy, or ECT); (3) augmentation or adding other treatment to the 
one already in use, such as a different drug, psychotherapy, or ECT (Table 1). 
Regardless of the strategy, it is recommended always to use one strategy at a time 
to assess which is the most effective. We will review each one of them.
2.4.1.1 Optimization
Optimization consists of improving the current treatment, while supervising 
good tolerance. It should be noted that, in some studies with patients diagnosed 
as resistant and sent to specialized clinics, it has been reported that an important 
number of them did not receive an appropriate dose of the medication or had been 
taking it behind for a brief period of time [51]. This would represent a case of 
pseudo-resistance. Several studies show that it is important to treat a major depres-
sive episode for 6–12 weeks before concluding non-remittance [6, 26, 52]. A study in 
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1627 patients, where 67% of them received less than 4 weeks of treatment and did 
not show response to an antidepressant [53], did not find any difference between 
continuing the current treatment or changing to another antidepressant. This sup-
ports the importance of keeping the patients on an antidepressant treatment for an 
appropriate amount of time before changing it. On the other hand, multiple studies 
show that if patients have less than 25% reduction of symptoms after 4 weeks treat-
ment, it could be indicated to switch to a different treatment strategy [54].
2.4.1.2 Treatment switching
Treatment switching is the act of suspending the current treatment and replacing 
it with a different pharmacologic or non-pharmacologic anti-depressive strategy. 
This includes using a different antidepressant, switching to psychotherapy, or ECT.
2.4.1.3 Changing antidepressants
It has been suggested that, in order to switch antidepressant medications, the 
current medication should be gradually discontinued while the new one is slowly 
introduced throughout 1–2 weeks and the dosage of the new antidepressant agent 
should be given at a corresponding amount to the one being discontinued. The clini-
cian should be aware of increases of adverse effects and, in relation to SSRIs, the risk 
of serotonin syndrome. Some clinicians prefer to switch from an SSRI to another 
instantly, except when the patient has received fluoxetine, where the waiting time 
should be no less than 4 weeks before using another SSRI due to its long half-life.
For patients resistant to SSRIs, it has been suggested to switch to a selective nor-
adrenaline and serotonin reuptake inhibitor (SNRI), atypical antidepressants, such as 
bupropion or mirtazapine, tricyclic antidepressants, or MAOIs. There are, however, 
few studies that compare switching to each one of these groups of drugs. In one 
meta-analysis that included four randomized studies with 1496 patients resistant to 
an SSRI, remission was evident in 24% of the patients who received another SSRI, and 
in 28% who were introduced to a different class of antidepressant such as bupropion, 
mirtazapine, or venlafaxine [55]. Regarding patients resistant to SSRI, many studies, 
including some meta-analyses, support changing to venlafaxine [17, 55]. A meta-
analysis with 3375 patients with depression resistant to an SSRI showed that changing 
to another SSRI led to remission on 45% of the subjects, but 54% remitted when 
changing to venlafaxine [17]. Concerning atypical antidepressants, the few compara-
tive studies available on TRD patients have not found differences respecting efficacy 
[18, 42]. In a group of patients resistant to paroxetine, a study that compared extended 
Table 1. 
Treatment strategies for resistant depression.
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release venlafaxine (225 mg/day) and mirtazapine (45 mg/day) found remissions of 41 
and 36% respectively [56]. In another study, 477 patients resistant to an SSRI treated 
for 14 weeks with bupropion SR (average dose 238 mg/day) or sertraline (average dose 
136 mg/day) remission was achieved on 21 and 18% of the subjects, respectively [57]. 
An 8-week study that compared mirtazapine (45 mg/day) with paroxetine (20 mg/
day) in 100 patients with TRD, remission was achieved in 36 and 47% with similar 
tolerance. Finally, a comparative study with mirtazapine (average dose 30 mg/day) 
and sertraline (average dose 120 mg/day) in 250 TRD patients, remission was similar 
(38 versus 28%, respectively) without statistical difference [58–60]. Nevertheless, 
there were more adverse effects with mirtazapine such as sedation, fatigue, weight 
gain, and xerostomia. In TRD patients, efficacy and tolerability of tricyclic antide-
pressants is comparable to that of atypical antidepressants and SSRIs [61]. Currently, 
tricyclic antidepressants have become the fourth or fifth line of treatment in TRD 
patients due to undesired adverse effects such as anticholinergic effects, cardiotoxic-
ity, and lethal potential with overdose. The STAR*D study reported the fourth or fifth 
line of treatment in major depressive patients due to undesired adverse effects such 
as anticholinergic effects, cardiotoxicity, and lethal potential with overdose. In TRD 
patients, efficacy and tolerability of tricyclic antidepressants is comparable to that of 
atypical antidepressants and SSRIs. In the STAR*D study, an open 14-week trial in 235 
patients compared nortriptyline (average dose 97 mg/day) with mirtazapine (average 
dose 42 mg/day) showing a comparable remission of 20 versus 12% and equal toler-
ance [62]. In a double-blind randomized study, 168 imipramine- or sertraline-resistant 
patients treated for 12 weeks were randomly assigned to the other treatment [63]. 
Remission was comparable (23% versus 32%) with more discontinuation with imip-
ramine switching due to adverse effects (9 versus 0%). MAOIs are rarely used today, 
since they carry lethal potential by interacting with other drugs and food containing 
tyramine [64]. Nevertheless, changing to a MAOI may still be helpful for some TRD 
patients [17, 64]. A randomized trial with 46 imipramine-resistant patients who 
received phenelzine (45–90 mg/day) for 6 weeks and 22 phenelzine-resistant patients 
who were switched to imipramine (150–300 mg/day) reported a higher response on 
patients who received phenelzine rather than imipramine (67 versus 41%) [64]. For 
severely depressed patients with TRD, there is not enough evidence that indicates 
which kind of antidepressant is superior [65]. Tricyclic antidepressants may be pre-
ferred [66]. However, a meta-analysis of 25 randomized trials on 1377 hospitalized 
depressed patients who received tricyclic antidepressants or SSRIs showed that tricyclic 
antidepressant superiority over SSRIs was low with a higher rate of adverse effects [67].
2.4.1.4 Switching to psychotherapy
Changing from a pharmacologic approach to psychotherapy may be rejected by 
many TRD patients [68], but still is a reasonable approach. A 12-week trial with 122 
patients who did not respond to citalopram and were randomized to cognitive behav-
ioral therapy (CBT) or different antidepressants (bupropion, sertraline, or venlafax-
ine) [68] reported similar remission (25 and 28%). Another study with 140 patients 
who did not respond to a trial with nefazodone or CBT and then were switched to the 
other treatment [69] reported a comparable remission of 36 and 27%, respectively.
2.4.1.5 Electroconvulsive therapy
For patients with TRD with severe depression, ECT continues to be the therapy 
of choice [28, 66, 70–72]. The most important indications for ECT are persistence 
of suicidal ideation, suicide attempt, severe weight loss with malnutrition, dehydra-
tion, food or fluids rejection, and malignant catatonia. ECT is also indicated in cases 
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of depression with psychotic symptoms and if there is previous history of response 
to this treatment. ECT has been shown superior to pharmacotherapy as shown by 
multiple meta-analyses and randomized studies [65]. A meta-analysis of 18 studies 
with 1144 patients that compared ECT with pharmacotherapy found that ECT was 
more effective [71]. ECT approach is recommended by many guidelines [66, 70, 
72, 73]. ECT is not exempt of anesthetic risks, adverse effects, logistic problems, 
treatment rejection, and relapse.
2.4.1.6 Augmentation
Augmentation consists of adding other treatment (pharmacologic or non-
pharmacologic) to the current one [74]. A new drug, psychotherapy, or transcranial 
magnetic stimulation (TME) might be added. This approach has been widely used 
and studied; combination therapy with antipsychotics, lithium, or triiiodothyro-
nine (T3) are generally well tolerated [52, 58, 75–79], while combination therapy of 
MAOI with other antidepressants may cause serotonin syndrome or hypertensive 
crisis [80]. Previous response, safety, comorbidities, ease of use, patient’s prefer-
ence, and costs are factors to consider while adding other drugs to the current treat-
ment. TRD patients, who have had additions and do not respond in 6–12 weeks at 
the desired dose or do not tolerate the combination, should be switched to a second 
combination [58]. Some authors suggest discontinuation of the supplementary drug 
and addition of a new one progressively over 1–2 weeks [58].
2.4.1.7 Adding a second antidepressant
Concerning depression with partial response to monotherapy with antidepres-
sants, a second drug is usually added. However, a meta-analysis of eight studies 
with 808 patients that did not respond to monotherapy and that compared anti-
depressant combination with monotherapy, found a similar improvement on both 
groups [81]. The most studied antidepressants are mirtazapine and bupropion.
Mirtazapine use as an augmentation drug on TRD patients is supported by the 
results of open and placebo-controlled studies [81, 82]. On the STAR*D study, 
mirtazapine was added to patients resistant to venlafaxine and was compared with 
switching to tranylcypromine (a MAOI). Both approaches had no different effects 
[83]. However, addition of mirtazapine to resistant patients requires additional 
studies to establish its efficacy.
Bupropion, a noradrenergic/dopaminergic reuptake inhibitor, was studied in 
TRD patients [84]. Bupropion has a good tolerability and low side effect profile, 
including few sexual side effects.
Buspirone, a serotonin (5-HT1A) receptor partial agonist, was studied in ran-
domized, double-blind, placebo-controlled trials combined with an SSRI in patients 
with TRD [85]. Buspirone, at a dosage of 41 mg/day, was compared on the STAR*D 
study with Bupropion SR at 267 mg/day, with similar effectiveness [44]. As with 
mirtazapine, bupropion addition is a popular practice as an enhancing maneuver, 
but additional studies are needed to justify its use on TRD patients.
2.4.1.8 Second-generation antipsychotics
For second-generation antipsychotics in patients with TRD, the following order 
was suggested based on benefit and a lower rate of adverse effects: aripiprazole, 
quetiapine, risperidone, and less frequently ziprasidone or olanzapine [58, 77, 86, 87]. 
Also, the use of brexpiprazole has been suggested if aripiprazole generates akathi-
sia [88, 89]. The analysis of 16 studies comparing the addition of aripiprazole, 
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olanzapine, quetiapine, or risperidone with placebo on 3480 patients with 
non-psychotic depression who failed to at least one attempt with antidepressant 
monotherapy [90] showed improvement in 31% of the patients who received the 
additional drug (31%) versus placebo (17%). Discontinue due to adverse effects was 
higher with antipsychotics (9 versus 2%), 4% for aripiprazole, 12% for quetiapine, 
and 7% for risperidone [90]. In an open, randomized 12-week trial with 1522 
patients who stayed severely depressed after treatment with an antidepressant [75], 
the subjects received three types of treatments: aripiprazole increase (target dose 
5–15 mg/day), bupropion increase (target dose 300–400 mg/day), or switching 
to bupropion. Response (reduction equal or higher than 50% of depression) was 
greater with aripiprazole (74%) than increasing bupropion (66%) or switching 
to bupropion (62%). There were more adverse effects with aripiprazole, such as 
akathisia, somnolence, weight gain, and laboratory abnormalities, but patients 
experienced more anxiety with bupropion. A meta-analysis of 11 randomized trials 
on TRD patients (n > 3000) found that effectiveness of the augmentation of atypi-
cal antipsychotics might rise with the increase of the resistance [90]. For example, 
the augmentation may carry more benefit for patients that do not respond to three 
or four failed attempts compared with those who do not respond to one.
2.4.1.9 Lithium
Augmentation of treatment with lithium was reported for the first time by De 
Montigny by combining it with tricyclic antidepressants [91]. Thereafter, multiple 
studies have demonstrated its efficacy. A meta-analysis of 10 placebo, controlled stud-
ies showed that the addition of lithium at a dose to 600–900 mg/day (plasma levels 
higher than 0.4 mEq/L) was superior to placebo [78, 92]. A meta-analysis of nine 
trials with 237 patients comparing lithium versus placebo found a higher response 
with lithium [84]. Lithium was effective in the augmentation with first- and second-
generation antidepressants attached to a possible benefit in reducing suicide risk. A 
meta-analysis of nine studies with 234 patients, where double-blind trials with lithium 
and placebo on TRD patients were included, showed a broad effectiveness with this 
approach [93]. The authors concluded that it should be given for no less than 7 days 
at dose of 600–800 mg/day [93]. An analysis of the literature reviewing 12 random-
ized studies on lithium augmentation of SSRIs or atypical antipsychotic drug therapy 
found no statistical difference that favors the use of one approach or the other [94].
2.4.1.10 Thyroid hormone
Thyroid hormone, in particular T3, has been used as an augmenting agent since 
the 1960s [95]. The usual dose of T3 in the form of liothyronine is 25–50 pg and 
with thyroxine (T4) is 150 pg. An initial meta-analysis with T3 showed effectiveness 
against placebo [79]. Subsequent studies, however, have shown limited evidence 
of its effectiveness. A meta-analysis with four randomized studies with 95 patients 
who did not respond to tricyclic antidepressants compared augmentation with T3 
versus placebo or T4 showed response in 53% patients who received T3 but had 
not statistical difference with placebo [79]. However, T3 augmentation is not very 
popular in the UK nor in the USA [96].
2.4.1.11 Repetitive transcranial magnetic stimulation
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive technique 
in which a sequence of high-intensity magnetic pulses is used to stimulate cortical 
neurons to treat neuropsychiatric disorders including major depressive disorder 
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[97]. This technique may be ambulatory, can be added to the current antidepressant 
treatment, and has good tolerability. Initial systematic reviews on mixed popula-
tions of depressed patients that included non-resistant patients supported their use 
on TRD patients [98–103]. A meta-analysis of 24 trials that included 1092 patients 
who underwent rTMS and sham conditions showed rTMS was superior in clinical 
improvement of patients with TRD. The response and remissions were 25 and 17% 
and 9 and 6% for the rTMS and sham conditions, respectively [104]. Short duration 
rTMS (1–4 weeks) has an evident antidepressant effect on TRD patients and is well 
tolerated. Nevertheless, remission rates and responses with rTMS are low and it is 
unknown if there is a sustained effect. Not known is whether effects of TMS are 
sustained over time and its speed of onset [104].
2.4.1.12 Psychotherapy
Addition of CBT usually helps TRD patients, as demonstrated by multiple ran-
domized studies [105–107]. In a randomized 1-year study with CBT (12–18 sessions), 
it was observed that remission occurred more on CBT group of patients (28%) than 
in patients who did not receive it (15%). In another study, depressive symptoms were 
minor on a self-report 40 months after patients received CBT [108]. A 12-week study 
compared citalopram plus 16-session CBT with citalopram plus additional phar-
macological approaches such as bupropion or buspirone in 182 ambulatory patients 
resistant to citalopram [109]. The number of patients who achieved remission was 
similar (23 and 33%). A 12-week study that compared nefazodone treatment with 
16- to 20-session CBT versus nefazodone alone on 446 ambulatory patients with 
chronic depression (medium of 8 years) showed remission in more patients under-
going the combination (48 versus 29%) [110]. In hospitalized patients with severe 
depression, combination therapy is a common practice and its effectiveness is clear. 
A 12-week study that compares CBT and pharmacotherapy with pharmacotherapy 
alone in 20 hospitalized patients with chronic depression found a similar improve-
ment [111]. An observational 12-week study with CBT added to pharmacotherapy 
in 24 hospitalized patients with chronic depression [112] found a 46% reduction in 
depressive symptoms. In TRD patients, other types of psychotherapy such as group, 
family, or interpersonal therapy have not been well studied.
2.4.1.13 Other addition maneuvers
Several addition maneuvers have been employed in TRD patients, such as 
lamotrigine combination, stimulants like methylphenidate, modafinil, and pindolol 
among others. A meta-analysis which included 10 studies with 289 patients undergo-
ing lamotrigine treatment concluded that this drug had little effect on non-bipolar 
TRD patients [113]. Controlled studies evaluating placebo versus methylphenidate 
have been negative despite its regular use [114]. Modafinil did not show a sustained 
effect in two controlled studies. However, a subsequent retrospective analysis 
suggests that modafinil may help TRD patients with fatigue and somnolence [115]. 
Pindolol, a non-selective beta-adrenergic antagonistic with effect in the 5-HT1A 
auto-receptor has shown negative results against placebo on TRD patients [116]. 
N-methyl-D-aspartate (NMDA) receptor acting drugs like memantine, ketamine, 
and riluzole have been studied. Controlled studies with memantine, an NMDA-
receptor antagonist, have been negative [117]. Ketamine, an NMDA-receptor 
antagonist anesthetic, has shown positive antidepressant results in a controlled 
study against placebo in patients with TRD [118]. Riluzole, a putative glutamate 
release inhibitor used in the treatment of amyotrophic lateral sclerosis, did not show 




2.4.2 Studies comparing switching versus augmentation maneuvers
Multiple guidelines suggest how to use augmentation or switching maneuvers 
(The American Psychiatric Association, United Kingdom National Institute 
of Health and Clinical Excellence guidelines among others) [28, 66, 120, 121]. 
However, few randomized studies comparing the effectiveness of these maneuvers 
on TRD patients have been performed and most of them do not differ between 
those patients with little or no benefit from those who improve partially.
Various studies show that augmentation or switching maneuvers are equally 
efficient. Thus, multiple evaluations reviewing placebo-controlled randomized 
studies regarding augmentation and switching approaches show similar results 
[76]. The medium rate of remission with augmentation was 27% and switching 
was 22%, with response rates (reduction of 50% or more of the symptoms) of 38 
and 40%, respectively [122]. A prospective study with citalopram on two groups of 
269 patients who preferred augmentation with bupropion or buspirone to switch-
ing citalopram to bupropion, sertraline, or venlafaxine had a similar remission. A 
randomized study with 375 TRD patients, where several treatments were assigned, 
including five augmentations and two switching options [123, 124] showed similar 
results with 37 and 41% for each strategy. On the other hand, in a group with 1522 
patients (85% men), almost 50% of them undergoing post-traumatic disorder, 
and who continued severely depressed after the first course of treatment with an 
antidepressant, almost all of them on psychotherapy, the augmentation approach 
with aripiprazole (5–15 mg/day) or bupropion (300–400 mg/day) was slightly 
superior to switching antidepressants to bupropion as monotherapy [75]. Remission 
was achieved in 29% of the patients with aripiprazole augmentation, 27% with 
bupropion augmentation, and 22% with switching to bupropion. Surveillance over 
24 months of the remitted patients (n = 396) showed that approximately 25% of the 
patients in each group relapsed. There were more adverse effects in the aripiprazole 
group [75]. Other studies show that augmentation approach with aripiprazole may 
be more effective in women than in men [125].
With patients not tolerating the antidepressant dose, it is preferable to switch 
antidepressants. While there is evidence that suggests that augmentation is somehow 
superior to switching antidepressants, the decision should be discussed with the 
patient. Clinical criteria would be that patients who have had partial benefit from 
the initial antidepressant and have few adverse effects may prefer an augmentation 
approach and those with less improvement and more adverse effects might prefer 
switching medication. However, in patients resistant to a second treatment, there is no 
evidence that shows how many approaches should be done before considering change 
of treatment. Authors suggest 1–3 trials before switching [58, 74]. Changing medica-
tions has the advantage of achieving a better compliance to treatment than when more 
than one medication is used [126] adding a lower risk of adverse effects, pharmaco-
logic interactions, and costs. A study evaluated 48 trials that included 6654 patients. 
A comparison was made between randomized studies, which compared 11 agents 
used on augmentation approaches: atypical antipsychotics (aripiprazole, olanzapine, 
quetiapine, and risperidone), antidepressants (bupropion, buspirone), lithium, thy-
roid hormone, methylphenidate, pindolol, and lamotrigine [87]. The studies analyzed 
were compared between them or placebo in patients with TRD and the proportion 
of patients who responded to treatment was defined as primary effectiveness. The 
analysis showed that primary effectiveness was higher with quetiapine, aripiprazole, 
thyroid hormone, and lithium in relation to placebo, but even higher for the former 
two in the sensibility analysis. There were no differences regarding discontinuation 
rate and adverse effects (acceptability) for these treatments [87]. Quetiapine, olan-
zapine, aripiprazole, and lithium were less well tolerated than placebo [87].
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A randomized 8-week study on 140 TRD patients with paroxetine plus risperi-
done, paroxetine plus trazodone, and paroxetine plus thyroid hormone showed 
similar remission rates of 27, 43, and 38%, respectively [123]. A 6-week randomized 
open study that compared adding quetiapine (target dose 300 mg/day) with adding 
lithium (target plasma concentration from 0.6 to 1.2 mmol/L) in 450 resistant 
patients got a similar remission rate of 32 and 27%, respectively [127].
A meta-analysis with 48 randomized trials (n > 6000 depressed patients) in 
which efficiency of augmentation agents was evaluated using results from compari-
sons between drugs (on head to head trials), as well as indirect comparisons of the 
drugs through their relative effects with a common comparator (typically a pla-
cebo) [123]. The response (reduction equal or higher than 50%) or remission was 
more frequent when aripiprazole, lithium, olanzapine, quetiapine, risperidone, or 
thyroid hormone (T3 or T4) was added, compared to placebo; results from each one 
were comparable. Discontinuation due to adverse effects was higher with aripipra-
zole, lithium, olanzapine, and quetiapine than with placebo.
2.4.3 Promising new treatments
2.4.3.1 Acetylcholine receptor acting drugs
Medications that act on the cholinergic system seem promising in the treatment 
of TRD patients. Controlled studies versus placebo with intravenous scopolamine 
(a muscarinic antagonist) in TRD patients showed promising results [128]. 
Mecamylamine, a nAChR antagonist added to citalopram, was also superior to 
placebo [129]. Other drugs like mecamylamine, S-mecamylamine, and varenicline 
are currently in a preliminary stage of study in depressive patients [129, 130].
2.4.3.2 N-methyl-D-aspartate (NMDA) acting drugs
Ketamine, an NMDA-receptor antagonist, has shown antidepressant effects in 
TRD patients in a controlled study versus placebo [118]. However, ketamine, a dis-
sociative anesthetic administration which complicates TRD patient treatment due 
to its route of administration (intravenous), requires hospitalization and consulta-
tion with an anesthesiologist. The rapid effects of ketamine usually disappear in 
4–6 days. Also, it is possible that patients who improve on ketamine require a long-
term course of maintenance. Ketamine has been given intranasal, or by sublingual 
delivery. Lapidus et al. [131] compared intranasal administration of ketamine 50 mg 
and placebo in 20 TRD patients. Patients improved at 24 h, but not at 72 h after 
administration. Recent studies are currently researching intranasal administration 
of esketamine, the S-enantiomer of racemic ketamine on TRD patients. Initial 
results are very promising [132]. If accepted, esketamine would enter the list of 
enhancement approaches for TRD patients.
Deep brain stimulation, vagus nerve stimulation, and neurosurgical lesions have 
also been evaluated in different studies as therapeutic options in highly resistant 
TRD patients [133].
2.5 Neurobiological aspects of resistant depression
Most antidepressants act by modulating serotonin, noradrenaline, and dopa-
mine neurotransmission, but other neurotransmission routes seem to be involved 
such as cholinergic, glutamatergic, neuropeptides, and neuromodulators among 
others. The complex neurotransmission systems are prone to failure in the short- 




treatments seem to exert action by different mechanisms modulating different 
cerebral regions [134]. Genetic variants may explain up to 42% of antidepressant 
response [135]. Genetic polymorphisms for cytochrome P-450 (CYP) enzymes 
may lead to a reduction on enzyme activity of the CYP2D6 or CYP3A4 variants, 
leading to intolerance to antidepressants on high plasmatic levels [136, 137]. Some 
patients are rapid metabolizers, resulting in low plasmatic levels at standard doses 
of antidepressants, leading to resistance. Evaluation of these genetic variants is 
accessible with pharmacogenetic studies of antidepressants. Other resistance 
genetic variants may be related to p-glycoprotein (p-gp), also known as the ABCB1 
drug multiresistance gene [138]. Besides this, other polymorphic variants have 
been associated with response to antidepressants. In the case of serotonin 2A gene 
(HTR2A), both coding and noncoding polimorphisms have been associated to low 
SSRIs response [139–141]. Furthermore, single nucleotid polymorphisms (SNPs) 
of the genes for brain-derived neurotrophic factor (BDNF) [142, 143], the norepi-
nephrine transporter [144], tryptophan hydroxylase 2 [145, 146], corticotrophin 
releasing hormone receptor 1 [147], the glucocorticoid receptor [148, 149], and the 
common promoter polymorphism of the serotonin transporter gene [150–155] have 
been associated with low SSRI response.
It has been published that the activation of the immune system and neuroin-
flammation represent a primary event in the pathophysiology of TRD [156–158] 
and that the effect of NSAID may increase the effect of antidepressants [159].
Finally, the catecholaminergic hypothesis of depression [160, 161], which asso-
ciates depression with low levels of neurotransmitters, was accepted to explain 
not only the neurobiochemistry of depression, but also the effect of antidepres-
sant drugs. This hypothesis postulates that, in depression, the function of the 
dopamine, noradrenaline, and indolamine serotonin monoamines is decreased. In 
support of this, different studies have shown changes in plasma, urine, and cere-
brospinal fluid concentrations of these neurotransmitters and their metabolites, 
changes in the density of neuroreceptors in platelets and neurons, flattened curves 
in neuroendocrine challenges and also early relapses with the blockade of restric-
tion enzymes for neurotransmitter synthesis in patients who had achieved depres-
sion remission with antidepressant treatment [162]. The existence of subtypes 
of depression, where noradrenergic, serotoninergic, or dopaminergic negative 
balance is predominant, has been also postulated. Patients with these subtypes 
of depression hypothetically would respond better to antidepressant drugs with 
noradrenergic, serotoninergic and dopaminergic effects. Unfortunately, clinical 
studies on the effect of antidepressants with different mechanisms of action show 
contradicting results, and today there are not clear clinical or biological parame-
ters to predict the results of different antidepressant treatments [163]. It should be 
noted that any theory about the cause of TRD would be simplistic including that 
the deficit of a single neurotransmitter, genetic, or immune system and neuroin-
flammation responses would be present in most TRD patients. However, knowing 
if there are groups of patients that may respond better to drugs with different 
mechanisms of action continues to be important for the treatment of patients with 
TRD [164].
It has been suggested that, in the selection of an antidepressant drug, the clini-
cian must observe the overall response of the patient with major depression [165]. 
Also, in the selection of an antidepressant drug, the clinician must observe the pos-
sible relationship between the drug’s biochemical effect and its effects on specific 
symptoms but also on adverse events. This became more relevant when a drug or 
group of drugs have failed to improve the patient and a new one has to be supplied, 
when adverse events force treatment change or when augmentation or change of 
antidepressant treatment is considered.
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3. Conclusions
Once resistance to treatment with two drugs with different action mecha-
nisms has been established, the next best therapeutic decision is terra ignota 
because there is not enough scientific information available to validate which 
steps are to follow: whether change treatment, adding an antidepressant, “buster 
therapies” like addition of lithium, thyroid hormone or stimulants, add atypical 
antipsychotics, rTMS or employment of newly treatments such as ketamine, or 
ECT. In the evaluation stages for the treatment of a patient with TRD it is impor-
tant to make an evaluation and reassessment of the case. This includes confirm-
ing the diagnosis of major depressive disorder, making the differential diagnoses 
of bipolar depression or other forms of resistant depression such as secondary 
to other medical issues, drugs, etc. Medical and psychiatric comorbidities, as 
well as depression severity should be assessed. Also, a detailed clinical history on 
antidepressant use should be performed. The application of diagnostic tools or 
evaluation scales is relevant.
Despite of its importance and frequency, there is no consensus over what TRD 
is. Advances have been made over assessment tools to evaluate resistance to treat-
ment. However, there is no consensus over which is the best stratification system 
for TRD. There is a lack of research that validates which treatment approaches 
may be more effective and which ones should be used in the different stages in the 
management of a resistant patient. Unfortunately, advances over neurobiology of 
depression cannot be transferred yet to a clinical level to help the physician choose 
the best treatment for a patient with major depression and even less so for a TRD 
patient [163, 164]. In patients who have an inadequate response to the first line of 
treatment, the clinician has many options to change the treatment, but if the second 
approach fails, other approaches seem to be equally effective in according to what 
is published on the literature and there are no clear guidelines that support one or 
the other. This outlook is discouraging for patients and physicians who are on trial 
and error until they find something that helps the patient. Future research on TRD 
patients should be centered on neurobiological factors involved in the development 
of the resistance including pharmacogenetics. Without the development of tech-
niques that help us predict which factors are related to this phenomenon, treatment 
of TRD patients will continue to be insufficient.
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